1.70p+0.05 (+3.03%)01 Nov 2024, 16:23
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Ovoca Bio PLC Fundamentals

Company NameOvoca Bio PLCLast Updated2024-11-01
IndustryBiotechnologySectorHealthcare
Shares in Issue81.564 mMarket Cap£1.39 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-€0.06EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.3850Cash Equity Ratio1.3064
Quick Ratio3.5921Current Ratio3.59
Price To Book Value0.7338ROCE0

Ovoca Bio PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Ovoca Bio PLC Company Financials

Assets202320222021
Tangible Assets00€18,000.00
Intangible Assets0€4.43 m€5.78 m
Investments00€1.95 m
Total Fixed Assets0€4.43 m€7.75 m
Stocks0€43,000.00€94,000.00
Debtors€106,000.00€1.22 m€319,000.00
Cash & Equivalents€3.34 m€3.70 m€6.59 m
Other Assets000
Total Assets€3.47 m€9.40 m€14.77 m
Liabilities202320222021
Creditors within 1 year€967,000.00€1.77 m€1.34 m
Creditors after 1 year000
Other Liabilities€439,000.00€214,000.000
Total Liabilities€967,000.00€1.77 m€1.34 m
Net assets€2.50 m€7.63 m€13.43 m
Equity202320222021
Called up share capital€11.06 m€11.06 m€11.06 m
Share Premium000
Profit / Loss-€5.10 m-€5.61 m-€5.25 m
Other Equity€2.50 m€7.63 m€13.43 m
Preference & Minorities000
Total Capital Employed€2.50 m€7.63 m€13.43 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.38501.38501.3850
Cash / Equity1.30641.30641.3064
EPS-€0.01-€0.06-€0.06
Cash Flow202320222021
Cash from operating activities€1.11 m-€5.16 m-€4.38 m
Cashflow before financing€236,000.00-€4.26 m-€4.38 m
Increase in Cash-€366,000.00-€2.89 m-€4.15 m
Income202320222021
Turnover000
Cost of sales000
Gross Profit000
Operating Profit-€5.10 m-€5.58 m-€5.33 m
Pre-Tax profit-€5.10 m-€5.61 m-€5.25 m

Ovoca Bio PLC Company Background

SectorHealthcare
ActivitiesOvoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX- Libicore - a novel synthetic peptide, administrated through a nasal spray.
Latest Interim Date25 Sep 2024
Latest Fiscal Year End Date28 Jun 2024

Ovoca Bio PLC Directors

AppointedNamePosition
2011-08-09Mr. John O'ConnorNon-Executive Director
2021-11-04Mr. Leonid Pavlovich SkoptsovNon-Executive Director
2011-08-09Mr. Roger William TurnerNon-Executive Director
2011-08-09Mr. Rowan MauleNon-Executive Director
2019-07-26Mr. Yuri Ivanovich RadchenkoNon-Executive Director
2020-09-28Mr. Mikhail Alexandrovich MogutovExecutive Director,Chairman
2024-10-11Mr. Timothy Rand McCutcheonExecutive Director,Chief Executive Officer
2018-08-09Mr. Donald SchisselNon-Executive Director
2024-07-15Mr. Kirill Andreyevich GolovanovExecutive Director,Chief Executive Officer (Interim)
2011-08-09Mr. Guido Edward Maria Pas BEdNon-Executive Director
2011-08-09Mr. Richard O'SheaNon-Executive Director
2011-08-09Dr. Barrie Williams Oakes, M. Sc.Non-Executive Director
2018-08-09Mr. Kenneth KuchlingNon-Executive Director
2021-12-30Mr. Romulo ColindresNon-Executive Director
2019-08-28Mr. Nikolay Myasodev Non-Executive Director
2022-01-31Mr. Christopher WiltshireExecutive Director,Chief Business Officer

Ovoca Bio PLC Contact Details

Company NameOvoca Bio PLC
Addressc/o OBH Partners, 17 Pembroke Street Upper, Dublin 2, D02 AT22
Telephone+353 17755600
Websitehttps://www.ovocabio.com

Ovoca Bio PLC Advisors

SolicitorOBH Partners
Phone+353 17755600
Fax+353 17755601
StockbrokerDavy Corporate Finance
Phone+353 16797788
Fax+353 16148727
BankAllied Irish Bank
RegistrarComputershare Investor Services (Ireland) Ltd
Phone+353 12163100
Fax+353 12163150
Nominated AdviserDavy Corporate Finance
Phone+353 16797788
Fax+353 16148727